Sugi Predict

Sugi Predict / Compounds / SCHEMBL2232230

SCHEMBL2232230

SCHEMBL2232230

Cc1cc(C)nc(OCCNc2ccc(NC(=O)C(=O)c3c(-c4ccccc4)cc4ccc(Cl)cn34)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.39
▸ HTT P42858 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALDH1A1 P00352 5/20 0.37
▸ MAPT P10636 4/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ THRB P10828 1/20 0.37
▸ HCRTR1 O43613 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ GAA P10253 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ LTB4R Q15722 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ ADK P55263 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646624 0.93 SMN1; SMN2 (0.41) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL2233127 0.92 LMNA (0.40) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1645448 0.90 LMNA (0.39) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1645550 0.87 SMN1; SMN2 (0.41) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1646589 0.87 LMNA (0.42) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL2231282 0.84 SMN1; SMN2 (0.41) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1646466 0.84 SMN1; SMN2 (0.42) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1987586 0.84 HCRTR2 (0.40) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1646757 0.84 HTT (0.37) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL1646302 0.83 HCRTR1 (0.38) LMNAHTTSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 — — EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 — — US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 LMNA 3870/4885HTT 1809/4885SMN1; SMN2 3682/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 LMNA 1805/4885HTT 3347/4885SMN1; SMN2 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.